FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003036666> ?p ?o ?g. }

• W2003036666 endingPage "454" @default.
• W2003036666 startingPage "444" @default.
• W2003036666 abstract "The objective of this review was to define a core set of recommendations for the treatment of HCV-associated mixed cryoglobulinemia syndrome (MCS) by combining current evidence from clinical trials and expert opinion.Expert physicians involved in studying and treating patients with MCS formulated statements after discussing the published data. Their attitudes to treatment approaches (particularly those insufficiently supported by published data) were collected before the consensus conference by means of a questionnaire, and were considered when formulating the statements.An attempt at viral eradication using pegylated interferon plus ribavirin should be considered the first-line therapeutic option in patients with mild-moderate HCV-related MCS. Prolonged treatment (up to 72 weeks) may be considered in the case of virological non-responders showing clinical and laboratory improvements. Rituximab (RTX) should be considered in patients with severe vasculitis and/or skin ulcers, peripheral neuropathy or glomerulonephritis. High-dose pulsed glucocorticoid (GC) therapy is useful in severe conditions and, when necessary, can be considered in combination with RTX; on the contrary, the majority of conference participants discouraged the chronic use of low-medium GC doses. Apheresis remains the elective treatment for severe, life-threatening hyper-viscosity syndrome; its use should be limited to patients who do not respond to (or who are ineligible for) other treatments, and emergency situations. Cyclophosphamide can be considered in combination with apheresis, but the data supporting its use are scarce. Despite the limited available data, colchicine is used by many of the conference participants, particularly in patients with mild-moderate MCS refractory to other therapies. Careful monitoring of the side effects of each drug, and its effects on HCV replication and liver function tests is essential. A low-antigen-content diet can be considered as supportive treatment in all symptomatic MCS patients. Although there are no data from controlled trials, controlling pain should always be attempted by tailoring the treatment to individual patients on the basis of the guidelines used in other vasculitides.Although there are few controlled randomised trials of MCS treatment, increasing knowledge of its pathogenesis is opening up new frontiers. The recommendations provided may be useful as provisional guidelines for the management of MCS." @default.
• W2003036666 created "2016-06-24" @default.
• W2003036666 creator A5000824601 @default.
• W2003036666 creator A5006054423 @default.
• W2003036666 creator A5007530796 @default.
• W2003036666 creator A5009245597 @default.
• W2003036666 creator A5009782649 @default.
• W2003036666 creator A5010288279 @default.
• W2003036666 creator A5010984168 @default.
• W2003036666 creator A5011182628 @default.
• W2003036666 creator A5012705049 @default.
• W2003036666 creator A5013492063 @default.
• W2003036666 creator A5017560677 @default.
• W2003036666 creator A5020517082 @default.
• W2003036666 creator A5026038725 @default.
• W2003036666 creator A5026508012 @default.
• W2003036666 creator A5029966387 @default.
• W2003036666 creator A5030466896 @default.
• W2003036666 creator A5035454801 @default.
• W2003036666 creator A5037120139 @default.
• W2003036666 creator A5040828721 @default.
• W2003036666 creator A5042277803 @default.
• W2003036666 creator A5043427640 @default.
• W2003036666 creator A5048428887 @default.
• W2003036666 creator A5050032872 @default.
• W2003036666 creator A5050088304 @default.
• W2003036666 creator A5051195983 @default.
• W2003036666 creator A5053293570 @default.
• W2003036666 creator A5054501484 @default.
• W2003036666 creator A5059586370 @default.
• W2003036666 creator A5065476359 @default.
• W2003036666 creator A5069066410 @default.
• W2003036666 creator A5070658930 @default.
• W2003036666 creator A5071426661 @default.
• W2003036666 creator A5072612033 @default.
• W2003036666 creator A5074671177 @default.
• W2003036666 creator A5074859861 @default.
• W2003036666 creator A5074960840 @default.
• W2003036666 creator A5078370156 @default.
• W2003036666 creator A5080993054 @default.
• W2003036666 creator A5086792856 @default.
• W2003036666 creator A5088891566 @default.
• W2003036666 creator A5090179703 @default.
• W2003036666 creator A5091506479 @default.
• W2003036666 date "2011-06-01" @default.
• W2003036666 modified "2023-10-14" @default.
• W2003036666 title "Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients" @default.
• W2003036666 cites W1945306171 @default.
• W2003036666 cites W1964985725 @default.
• W2003036666 cites W1965057295 @default.
• W2003036666 cites W1967429097 @default.
• W2003036666 cites W1968102557 @default.
• W2003036666 cites W1970450296 @default.
• W2003036666 cites W1970673979 @default.
• W2003036666 cites W1974817945 @default.
• W2003036666 cites W1977081412 @default.
• W2003036666 cites W1979922467 @default.
• W2003036666 cites W1981601132 @default.
• W2003036666 cites W1983621878 @default.
• W2003036666 cites W1983770985 @default.
• W2003036666 cites W1986416046 @default.
• W2003036666 cites W1991549431 @default.
• W2003036666 cites W1996511805 @default.
• W2003036666 cites W2000677416 @default.
• W2003036666 cites W2002041623 @default.
• W2003036666 cites W2008484708 @default.
• W2003036666 cites W2014790912 @default.
• W2003036666 cites W2015324588 @default.
• W2003036666 cites W2017235365 @default.
• W2003036666 cites W2019376718 @default.
• W2003036666 cites W2019482974 @default.
• W2003036666 cites W2019985783 @default.
• W2003036666 cites W2020607789 @default.
• W2003036666 cites W2022648937 @default.
• W2003036666 cites W2025338109 @default.
• W2003036666 cites W2027545702 @default.
• W2003036666 cites W2028453745 @default.
• W2003036666 cites W2030502706 @default.
• W2003036666 cites W2036818109 @default.
• W2003036666 cites W2040294410 @default.
• W2003036666 cites W2040537348 @default.
• W2003036666 cites W2040551777 @default.
• W2003036666 cites W2041088380 @default.
• W2003036666 cites W2044628656 @default.
• W2003036666 cites W2044784043 @default.
• W2003036666 cites W2046900942 @default.
• W2003036666 cites W2047215881 @default.
• W2003036666 cites W2047844822 @default.
• W2003036666 cites W2050067066 @default.
• W2003036666 cites W2050287837 @default.
• W2003036666 cites W2050402586 @default.
• W2003036666 cites W2053668889 @default.
• W2003036666 cites W2054646550 @default.
• W2003036666 cites W2056179599 @default.
• W2003036666 cites W2057940890 @default.
• W2003036666 cites W2059152128 @default.
• W2003036666 cites W2061389251 @default.
• W2003036666 cites W2061519346 @default.

• next